Exicure Announces Board and Committee Changes

Impact · against what's priced in

XCUR faces severe solvency and listing risks following a Nasdaq notice regarding minimum stockholders' equity and the suspension of its core clinical activities. The company is currently in a precarious state, exploring strategic alternatives while restructuring its board.

XCUR−0.50

No priced-in read yet

In context

The company has suspended its core clinical activities and received a Nasdaq notice for non-compliance with minimum stockholders' equity requirements, signaling high insolvency and delisting risk.

Read from the article alone

• XCUR
• biotechnology
• board changes
• corporate governance
• gene therapy
• nasdaq compliance
• sec filing
• strategic alternatives

Search tags